Hoth Therapeutics Joins NVIDIA Connect to Boost AI Research
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing breakthrough therapeutics today announced that it has been officially accepted into the NVIDIA Connect Program, a global initiative supporting innovative software and technology companies working with advanced computing and AI platforms. Acceptance into the NVIDIA Connect Program provides Hoth... The post Hoth Therapeutics Joins NVIDIA Connect to Boost AI Research first appeared on AI-Tech Park.
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing breakthrough therapeutics today announced that it has been officially accepted into the NVIDIA Connect Program, a global initiative supporting innovative software and technology companies working with advanced computing and AI platforms.
Acceptance into the NVIDIA Connect Program provides Hoth Therapeutics with access to a suite of accelerated computing resources, technical guidance, and marketing support, enabling the company to further strengthen its AI-powered research initiatives across its therapeutic pipeline.
Strategic AI Integration to Enhance Hoth’s R&D Capabilities
Through the NVIDIA Connect Program, Hoth Therapeutics will gain access to:
- NVIDIA GPU-accelerated developer tools to enhance computational-biology workflows, including target identification, protein-structure modeling, and preclinical data analytics.
- Technical expertise, SDKs, and APIs that can support algorithmic modeling across Hoth’s programs, including HT-001 (pruritus reduction), HT-KIT (mast-cell modulation), HT-ALZ (GDNF-based Alzheimer’s therapy), and its metabolic-disease initiatives developed in partnership with leading academic institutions.
- Co-marketing and technology enablement opportunities, increasing visibility of Hoth’s AI-driven approach to drug development.
Positioning Hoth for Accelerated Time-to-Market
Participation in the Connect Program is expected to streamline key aspects of Hoth’s R&D strategy, reducing computational bottlenecks and enhancing predictive modeling.
“Acceptance into the NVIDIA Connect Program is a meaningful milestone for Hoth,” said Robb Knie, Chief Executive Officer of Hoth Therapeutics. “NVIDIA is a global leader in accelerated computing and AI, and this partnership will enable us to leverage cutting-edge technology to enhance our drug-development programs, increase modeling speed, and improve the efficiency of our preclinical and clinical decision-making.”
The post Hoth Therapeutics Joins NVIDIA Connect to Boost AI Research first appeared on AI-Tech Park.
